Abstract
Glycogen storage disease type II (GSDII) is an autosomal recessive myopathy caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). Enzyme replacement therapy (ERT) with recombinant GAA (rh-GAA) has become available for GSDII, although its effectiveness in adults remains unknown. We present a case of ERT with rhGAA in a 49-year-old male with GSDII in a severe stage of the disease. Quantitative magnetic resonance imaging showed an increase in muscle mass of the inferior limb, especially evident on the quadriceps femoris and the patient’s body weight increased up to 30%, although his reported dietary habits were the same as before ERT. Beyond improvement in muscle strength and respiratory function, we observed a dramatic increase in body mass index from 12.7 to 16.6 kg/m2. This may reflect a change from a catabolic state to a more balanced metabolic state during ERT.
Similar content being viewed by others
References
Engel A, Hirschhorn R. Acid maltase deficiency. In: Engel A, Franzini-Armstrong C, eds. Myology. 2nd edition. New York, NY: McGraw-Hill; 1994(2):1533–1553.
Bodamer OA, Leonard JV, Halliday D. Dietary treatment in late-onset acid maltase deficiency. Eur J Pediatr. 1997;156(suppl 1):S39–S42.
Slonim AE, Bulone L, Goldberg T, et al. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve. 2007;35:70–77.
Reuser AJJ, Van den Hout JMP, Bijvoet AG, Kroos MA, Verbeet MP, Van Der Ploeg AT. Enzyme therapy for Pompe disease: from science to industrial enterprise. Eur J Pediatr. 2002;161(suppl 1):S106–S111.
Winkel LPF, Van den Hout JMP, Kamphoven JHJ, et al. Enzyme replacement therapy in late-onset Pompe’s disease: a three-year follow-up. Ann Neurol. 2004;55:495–502.
Ravaglia S, Pichiecchio A, Rossi M, et al. Dietary treatment in adult-onset type II glycogenosis. J Inherit Metab Dis. 2006;29:590.
Beck AT, Steer RA, Brown GK. Manual for Beck Depression Inventory II (BDI-II). San Antonio, TX: Psychology Corporation; 1996.
Tindall B. In: O’Brien MD, ed. Aids to the Examination of the Peripheral Nervous System. 3rd edition. London: Medical Research Council; 1986.
Gardner-Medwin D. Management of muscular dystrophy. Physiotherapy. 1977;63:46–51.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–1123.
Raben N, Fukuda T, Gilbert AL, et al. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther. 2005;11:48–56.
Demey HE, Van Meerbeeck JP, Vandewoude MF, et al. Respiratory insufficiency in acid maltase deficiency: the effect of high protein diet. JPEN J Parenter Enteral Nutr. 1989;13:321–323.
Slonim AE, Coleman RA, McElligot MA, et al. Improvement of muscle function in acid maltase deficiency by high-protein therapy. Neurology. 1983;33:34–38.
Sheffield-Moore M, Paddon-Jones D, Sanford AP, et al. Mixed muscle and hepatic derived plasma protein metabolism is differentially regulated in older and younger men following resistance exercise. Am J Physiol Endocrinol Metab. 2005;288:E922–E929.
Baumgartner RN, Koehler KM, Romero L, Garry PJ. Serum albumin is associated with skeletal muscle in elderly men and women. Am J Clin Nutr. 1996;64:552–558.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ravaglia, S., Danesino, C., Pichiecchio, A. et al. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II. Adv Therapy 25, 820–829 (2008). https://doi.org/10.1007/s12325-008-0086-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-008-0086-y